Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio - and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
